Report post
Investors sue biotech firm Acelyrin (SLRN) for alleged securities fraud, following a blockbuster IPO and lofty valuations. The lawsuit alleges Acelyrin misled investors, casting doubts on its drug's potential worth. Cramer's bullish prediction of $100 billion FDA approval value now hangs in the balance, as legal clouds gather over the company's future.

The World's Leading Crypto Trading Platform

Get my welcome gifts